Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Biomédica (Bogotá) ; 33(1): 99-106, ene.-mar. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-675137

ABSTRACT

Introducción. Colombia es el país de América con mayor proporción de casos nuevos de lepra con discapacidad grave. Para disminuir tal discapacidad se requiere el control de las reacciones, principal causa del daño neural en esta enfermedad. Objetivo. Describir las características clínicas y epidemiológicas y el tratamiento de los pacientes con reacciones de tipo 1 y 2 que consultaron al Centro Dermatológico Federico Lleras Acosta. Materiales y métodos. Se trata de un estudio descriptivo que incluyó la población de pacientes con diagnóstico clínico de reacciones de tipo 1 y de tipo 2 por lepra, que acudieron al centro entre los años 2003 y 2009. Resultados. Se estudiaron 96 reacciones, 35 del tipo 1 y 61 del tipo 2. El 75 % de los pacientes provenía de los departamentos de Tolima, Cundinamarca, Santander y Boyacá. El 56 % de las reacciones de tipo 1 se presentaron antes de iniciar la poliquimioterapia para la lepra; el dermatólogo tratante consideró que las reacciones que se presentaron después de suspender la poliquimioterapia eran recaídas. El 94 % de las reacciones de tipo 1 se trataron con corticoides orales. El 97 % de los pacientes con reacciones de tipo 2 presentaron eritema nudoso, y todos se trataron con talidomida. Conclusiones.La clínica de la reacción de tipo 1 puede orientar al diagnóstico de la lepra en un paciente sin el antecedente de esta enfermedad (56 %). La reacción de tipo 1 que se inicia después de suspender la poliquimioterapia para la lepra, podría ser una manifestación de recaída de la enfermedad. La reacción de tipo 2 es más frecuente en hombres, con una relación hombre a mujer de 4:1. El 97 % de los pacientes con reacción de tipo 2 presentó eritema nudoso.


Introduction: Colombia is the country in America with the highest proportion of new cases leprosy with severe disability. To decrease such disability it is necessary to control these reactions, the main cause of nerve damage in leprosy. Objective: To describe the clinical and epidemiological characteristics and the treatment of patients with type 1 and 2 leprosy reactions who consulted the Centro Dermatológico Federico Lleras Acosta. Materials and methods: It is a descriptive study which included patients with clinical diagnoses of type 1 and 2 reactions who were seen in the center between 2003 and 2009. The town of origin of the patients, their age, clinical features and treatments were analysed. Results: We studied 96 reactions in 87 patients, 35 type 1 and 61 type 2 reactions; 75% of the patients came from the departments of Tolima, Cundinamarca, Santander and Boyacá; 77% of type 1 reaction occurred before the beginning of multidrug therapy for leprosy. The reactions that started after stopping the multidrug therapy were considered as a leprosy relapse. Conclusions: Correct identification of type 1 reaction by the general practitioner will allow the diagnosis of leprosy in a large percentage of patients. The type 1 reaction that begins after stopping the leprosy multidrug therapy may be a manifestation of a relapse of the disease.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Erythema Nodosum/epidemiology , Leprosy/pathology , Colombia/epidemiology , Cytokines , Drug Therapy, Combination , Erythema Nodosum/etiology , Immune Complex Diseases/epidemiology , Immune Complex Diseases/etiology , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/complications , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/epidemiology , Leprosy, Lepromatous/immunology , Leprosy, Paucibacillary/drug therapy , Leprosy, Paucibacillary/pathology , Leprosy, Paucibacillary/physiopathology , Leprosy/drug therapy , Leprosy/epidemiology , Leprosy/physiopathology , Recurrence , Tertiary Care Centers/statistics & numerical data
2.
Asian Pac J Allergy Immunol ; 1989 Jun; 7(1): 15-21
Article in English | IMSEAR | ID: sea-36725

ABSTRACT

Circulating immune complexes are suspected as a potentially serious adverse effect after prolonged allergen immunotherapy. This study was undertaken to determine whether there were any significant immunological differences between 32 subjects with allergic rhinitis/asthma treated with immunotherapy of various durations and 13 subjects with similar diagnosis who had never been treated by immunotherapy. All patients were carefully examined for symptoms and signs of immune-complex diseases with negative results. The presence of circulating immune complexes was evaluated by the modified 125I-C1q binding test, the solid phase conglutinin (K) binding test and determination of C3, C4 and C3d levels. In addition, urinalysis, and quantitative determination of serum IgG, IgA, IgM and IgE were also performed. The overall results suggested that prolonged allergen immunotherapy did not result in an increase of circulating immune complexes or other adverse immunological consequences.


Subject(s)
Adult , Aged , Allergens/administration & dosage , Antigen-Antibody Complex/analysis , Asthma/immunology , Complement System Proteins/analysis , Desensitization, Immunologic/adverse effects , Female , Humans , Immune Complex Diseases/etiology , Immunoglobulin M/analysis , Male , Middle Aged , Rhinitis, Allergic, Perennial/immunology , Thailand , Time Factors
3.
Yonsei Medical Journal ; : 133-141, 1984.
Article in English | WPRIM | ID: wpr-82273

ABSTRACT

This study evaluates the pathogenesis of rheumatoid arthritis by producing immune complex induced arthritis with an intra-articular injection of BSA in immunized rabbits, and the effect of systemic administration of cyclophosphamide and local administration of anti-macrophage serum. The reduction of inflammatory reaction by cyclophosphamide administration appears to be caused mainly by selective depletion of the neutrophils, and partly by immune suppression. It appears that the rabbit abdominal macrophage has the common morphologic, functional and antigenic patterns with the M-type synovial lining cells. There is another possibility that the cross-reacting antigens between macrophage and the M-type cell of the synovial lining may exist. It is concluded that in this experimental immune complex arthritis, the site of localization of immune complexes seems to be the synovial, M-type cell, and the tissue injury of synovium is largely mediated not only by neutrophils and complement, but also by macrophages.


Subject(s)
Rabbits , Animals , Antigen-Antibody Complex , Arthritis, Rheumatoid/etiology , Cyclophosphamide/pharmacology , Immune Complex Diseases/etiology , Immune Sera/pharmacology , Macrophages , Serum Albumin, Bovine/administration & dosage , Synovial Membrane/pathology
SELECTION OF CITATIONS
SEARCH DETAIL